Abstract
Renal denervation (RDN) is currently confronted with the considerable heterogeneity of different post-procedural blood pressure responses. The challenges predominantly arise from not only the lack of selection of appropriate responders but also the absence of detection for the successful endpoints of intervention. In this paper, we summarize the significant characteristics of potentially appropriate hypertensive patients and propose a hopeful way to improve the accuracy of RDN, that is, the application of three-dimensional reconstruction technology combined with electrical renal nerve stimulation to guide the radiofrequency catheter ablation, which may promote the development of selective and accurate RDN in real-world clinical practice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397:2476–86.
Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Lobo MD, et al. Six-month results of treatment-blinded medication titration for hypertension control following randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO Trial. Circulation. 2019;139:2542–53.
Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395:1444–51.
Schmieder RE, Mahfoud F, Mancia G, Azizi M, Böhm M, Dimitriadis K, et al. European Society of Hypertension position paper on renal denervation 2021. J Hypertens. 2021;39:1733–41.
Ahmad Y, Francis DP, Bhatt DL, Howard JP. Renal denervation for hypertension: a systematic review and meta-analysis of randomized, blinded, placebo-controlled trials. JACC Cardiovasc Interv. 2021;14:2614–24.
Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390:2160–70.
Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391:2335–45.
Fengler K, Rommel KP, Blazek S, Besler C, Hartung P, von Roeder M, et al. A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN). Circulation. 2019;139:590–600.
Brouwers S, Sudano I, Kokubo Y, Sulaica EM. Arterial hypertension. Lancet. 2021;398:249–61.
Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391:2346–55.
Lauder L, Mahfoud F, Azizi M, Bhatt DL, Ewen S, Kario K, et al. Hypertension management in patients with cardiovascular comorbidities. Eur Heart J, 2023;44:2066–77.
Mahfoud F, Townsend RR, Kandzari DE, Kario K, Schmieder RE, Tsioufis K, et al. Changes in plasma renin activity after renal artery sympathetic denervation. J Am Coll Cardiol. 2021;77:2909–19.
Matanes F, Khan MB, Siddiqui M, Dudenbostel T, Calhoun D, Oparil S. An update on refractory hypertension. Curr Hypertens Rep. 2022;24:225–34.
Schmieder RE, Bosch A. Editorial comment: renal denervation. Hypertens Res. 2022;45:241–3.
Kario K, Yokoi Y, Okamura K, Fujihara M, Ogoyama Y, Yamamoto E, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res. 2022;45:221–31.
Gosse P, Cremer A, Kirtane AJ, Lobo MD, Saxena M, Daemen J, et al. Ambulatory Blood pressure monitoring to predict response to renal denervation: a post hoc analysis of the RADIANCE-HTN SOLO study. Hypertension. 2021;77:529–36.
Lauder L, Azizi M, Kirtane AJ, Böhm M, Mahfoud F. Device-based therapies for arterial hypertension. Nat Rev Cardiol. 2020;17:614–28.
Böhm M, Tsioufis K, Kandzari DE, Kario K, Weber MA, Schmieder RE, et al. Effect of heart rate on the outcome of renal denervation in patients with uncontrolled hypertension. J Am Coll Cardiol. 2021;78:1028–38.
Böhm M, Mahfoud F, Townsend RR, Kandzari DE, Pocock S, Ukena C, et al. Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. Eur Heart J. 2019;40:743–51.
Egan BM. Baseline heart rate predicts the blood pressure response to renal denervation in untreated hypertension. J Am Coll Cardiol. 2021;78:1039–41.
Mahfoud F, Mancia G, Schmieder R, Narkiewicz K, Ruilope L, Schlaich M, et al. Renal denervation in high-risk patients with hypertension. J Am Coll Cardiol. 2020;75:2879–88.
Fengler K, Rommel KP, Hoellriegel R, Blazek S, Besler C, Desch S, et al. Pulse wave velocity predicts response to renal denervation in isolated systolic hypertension. J Am Heart Assoc. 2017;6:e005879.
Kario K, Kagitani H, Hayashi S, Hanamura S, Ozawa K, Kanegae H. A Japan nationwide web-based survey of patient preference for renal denervation for hypertension treatment. Hypertens Res. 2022;45:232–40.
Verdecchia P, Cavallini C, Angeli F. Advances in the treatment strategies in hypertension: present and future. J Cardiovasc Dev Dis. 2022;9:72.
Gal P, de Jong MR, Smit JJ, Adiyaman A, Staessen JA, Elvan A. Blood pressure response to renal nerve stimulation in patients undergoing renal denervation: a feasibility study. J Hum Hypertens. 2015;29:292–5.
de Jong MR, Adiyaman A, Gal P, Smit JJ, Delnoy PP, Heeg JE, et al. Renal nerve stimulation-induced blood pressure changes predict ambulatory blood pressure response after renal denervation. Hypertension. 2016;68:707–14.
Liu H, Chen W, Lai Y, Du H, Wang Z, Xu Y, et al. Selective renal denervation guided by renal nerve stimulation in canine. Hypertension. 2019;74:536–45.
van Amsterdam WA, Blankestijn PJ, Goldschmeding R, Bleys RL. The morphological substrate for renal denervation: nerve distribution patterns and parasympathetic nerves. A post-mortem histological study. Ann Anat. 2016;204:71–9.
Cheng X, Zhang Y, Chen R, Qian S, Lv H, Liu X, et al. Anatomical evidence for parasympathetic innervation of the renal vasculature and pelvis. J Am Soc Nephrol. 2022;33:2194–210.
Kiuchi MG, Esler MD, Fink GD, Osborn JW, Banek CT, Böhm M, et al. Renal denervation update from the international sympathetic nervous system summit: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:3006–17.
Zhou H, Li Y, Xu Y, Liu H, Lai Y, Tan K, et al. Mapping renal innervations by renal nerve stimulation and characterizations of blood pressure response patterns. J Cardiovasc Transl. 2022;15:29–37.
Liu H, Li Y, Zhou H, Chen W, Xu Y, Du H, et al. Renal nerve stimulation identifies renal innervation and optimizes the strategy for renal denervation in canine. J Transl Med. 2023;21:100.
Sandhu A, Nguyen DT. Forging ahead: Update on radiofrequency ablation technology and techniques. J Cardiovasc Electr. 2020;31:360–9.
Leshem E, Zilberman I, Barkagan M, Shapira-Daniels A, Sroubek J, Govari A, et al. Temperature-controlled radiofrequency ablation using irrigated catheters: maximizing ventricular lesion dimensions while reducing steam-pop formation. JACC Clin Electrophy. 2020;6:83–93.
Tzafriri AR, Keating JH, Markham PM, Spognardi AM, Stanley JR, Wong G, et al. Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension. Sci Transl Med. 2015;7:265r–285r.
Okamura K, Satou S, Kato Y, Kogata Y, Matsushima M, Shirai K, et al. Intravascular ultrasound can be used to locate nerves, but not confirm ablation, during renal sympathetic denervation. J Clin Med Res. 2021;13:556–62.
Satou S, Okamura K, Konishi R, Shirai K, Urata H. Observation of renal sympathetic nerves by intravascular ultrasound. Hypertens Res. 2019;42:1092–4.
Acknowledgements
The authors are grateful to Liang Wang for his graphical artwork.
Funding
This work was partly supported by the National Natural Science Foundation of China (Grant Number: 32071110, YY and Grant Number: 82000471, WC)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Hu, X., Zhou, H., Chen, W. et al. Current problems in renal denervation and a hope to break the stage. Hypertens Res 46, 2654–2660 (2023). https://doi.org/10.1038/s41440-023-01380-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41440-023-01380-1